Head and neck cancers include nasopharyngeal carcinoma, oral cancer, oropharyngeal cancer's disease and laryngeal cancer. In order to conquer cancer and develop precise anticancer drugs, Lotte Medicine recently set up branches in Amsterdam, the Netherlands and Taipei, Taiwan Province Province, hoping to further deepen the European and Asian markets. The company is developing ASP- 1929 for the treatment of head and neck cancer, and is currently conducting phase III clinical trials, and will recruit patients with head and neck cancer in Taiwan Province Province to participate in the clinical trials.
ASP- 1929 has passed the "fast review channel" in the United States and Japan.
ASP- 1929 has been approved by the US Food and Drug Administration and the Japanese Ministry of Health, Labor and Welfare, and entered the third phase clinical trial for the treatment of recurrent head and neck squamous cell carcinoma. The second phase of further research has also been launched to assess whether this therapy is safe for other cancer patients.
Provide safe and effective anticancer drugs!
Hiroshi Mikitani, chairman and CEO of Lotte Medicine, pointed out that new anticancer drugs will be developed and popularized through patented photoimmunotherapy, so as to realize the concept of overcoming cancer and provide safe and effective therapeutic drugs for patients all over the world, thus changing and improving their lives.
Recruit patients with head and neck cancer in Taiwan Province for clinical trials.
Chen Yanting, general manager of Lotte Pharmaceutical Biotechnology Co., Ltd. in Taiwan Province Province, said that in Taiwan Province Province, oral cancer has been ranked in the top ten cancer rankings, and the mortality ranking has been moving forward from 10. The company's key product ASP- 1929 is used to treat head and neck cancer, and the third phase clinical trial is currently underway; Therefore, the team in Taiwan Province Province is currently recruiting patients for clinical trials in Taiwan Province, hoping to introduce innovative treatment methods into Taiwan Province Province as soon as possible in the future to improve the treatment effect of patients.
The Taipei office will expand the Asian market.
Lotte Pharmaceuticals said that the Amsterdam office will become the main office in Europe, while the German office, which started operation on 20 16, will serve as the research and development and production base of phototherapy equipment. The Taipei office, which is affiliated to the Japanese headquarters, will further expand the Asian market and be responsible for the promotion of post-marketing therapeutic drugs. The establishment of these two offices will enhance the R&D capability and global popularity of Lotte Medicine, which is a key layout; In addition, it can also bring more help to Lotte Medicine's ongoing global phase III clinical trials and more research in the future.
Join us and pay attention to your health every day! Line @ ID: @ Subscribe to Health Aloha Audio-visual Channel to read health knowledge more easily: /beauty/article/42509 Keywords: Hiroshi Mikitani, Head and Neck Cancer, ASP- 1929, Anticancer Drugs, Cancer, Lotte Medicine.